nodes	percent_of_prediction	percent_of_DWPC	metapath
Metyrapone—CYP2A6—prostate cancer	0.185	0.464	CbGaD
Metyrapone—CYP2E1—prostate cancer	0.131	0.329	CbGaD
Metyrapone—CYP3A4—prostate cancer	0.0825	0.207	CbGaD
Metyrapone—ABCC3—Conjugated Estrogens—prostate cancer	0.0757	0.203	CbGbCtD
Metyrapone—ABCC3—Etoposide—prostate cancer	0.0434	0.116	CbGbCtD
Metyrapone—CYP2E1—Estrone—prostate cancer	0.0339	0.0908	CbGbCtD
Metyrapone—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0326	0.0874	CbGbCtD
Metyrapone—ABCC3—Doxorubicin—prostate cancer	0.0296	0.0793	CbGbCtD
Metyrapone—CYP2E1—Mitoxantrone—prostate cancer	0.0202	0.054	CbGbCtD
Metyrapone—CYP3A4—Bicalutamide—prostate cancer	0.0171	0.0459	CbGbCtD
Metyrapone—CYP3A4—Estramustine—prostate cancer	0.0159	0.0427	CbGbCtD
Metyrapone—CYP3A4—Flutamide—prostate cancer	0.0142	0.0381	CbGbCtD
Metyrapone—CYP3A4—Abiraterone—prostate cancer	0.0142	0.0381	CbGbCtD
Metyrapone—CYP2E1—Etoposide—prostate cancer	0.0127	0.0341	CbGbCtD
Metyrapone—CYP3A4—Cabazitaxel—prostate cancer	0.0105	0.0282	CbGbCtD
Metyrapone—CYP3A4—Estrone—prostate cancer	0.0103	0.0275	CbGbCtD
Metyrapone—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00915	0.0245	CbGbCtD
Metyrapone—CYP3A4—Conjugated Estrogens—prostate cancer	0.00672	0.018	CbGbCtD
Metyrapone—CYP3A4—Mitoxantrone—prostate cancer	0.00611	0.0164	CbGbCtD
Metyrapone—CYP3A4—Estradiol—prostate cancer	0.0059	0.0158	CbGbCtD
Metyrapone—CYP3A4—Prednisone—prostate cancer	0.00507	0.0136	CbGbCtD
Metyrapone—CYP3A4—Etoposide—prostate cancer	0.00385	0.0103	CbGbCtD
Metyrapone—CYP3A4—Docetaxel—prostate cancer	0.00352	0.00944	CbGbCtD
Metyrapone—CYP3A4—Doxorubicin—prostate cancer	0.00263	0.00704	CbGbCtD
Metyrapone—CYP11B2—renal system—prostate cancer	0.00169	0.136	CbGeAlD
Metyrapone—CYP2E1—urine—prostate cancer	0.00154	0.124	CbGeAlD
Metyrapone—CYP3A4—urine—prostate cancer	0.00124	0.0998	CbGeAlD
Metyrapone—CYP2A6—prostate gland—prostate cancer	0.00117	0.0942	CbGeAlD
Metyrapone—ABCC3—prostate gland—prostate cancer	0.0011	0.0883	CbGeAlD
Metyrapone—CYP2A6—seminal vesicle—prostate cancer	0.000989	0.0797	CbGeAlD
Metyrapone—CYP11B2—lymph node—prostate cancer	0.000793	0.0639	CbGeAlD
Metyrapone—ABCC3—renal system—prostate cancer	0.000747	0.0602	CbGeAlD
Metyrapone—Angiopathy—Degarelix—prostate cancer	0.00063	0.00719	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Abiraterone—prostate cancer	0.000626	0.00715	CcSEcCtD
Metyrapone—Alopecia—Degarelix—prostate cancer	0.000613	0.007	CcSEcCtD
Metyrapone—Angiopathy—Cabazitaxel—prostate cancer	0.000593	0.00677	CcSEcCtD
Metyrapone—Hirsutism—Prednisone—prostate cancer	0.000589	0.00672	CcSEcCtD
Metyrapone—Skin disorder—Abiraterone—prostate cancer	0.000587	0.0067	CcSEcCtD
Metyrapone—Hypertension—Nilutamide—prostate cancer	0.000584	0.00667	CcSEcCtD
Metyrapone—Hypertension—Flutamide—prostate cancer	0.000581	0.00664	CcSEcCtD
Metyrapone—Alopecia—Cabazitaxel—prostate cancer	0.000578	0.0066	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Flutamide—prostate cancer	0.000569	0.0065	CcSEcCtD
Metyrapone—Bone marrow depression—Capecitabine—prostate cancer	0.000569	0.0065	CcSEcCtD
Metyrapone—CYP2E1—prostate gland—prostate cancer	0.000553	0.0445	CbGeAlD
Metyrapone—Dermatitis atopic—Docetaxel—prostate cancer	0.000536	0.00612	CcSEcCtD
Metyrapone—Skin disorder—Flutamide—prostate cancer	0.000534	0.0061	CcSEcCtD
Metyrapone—Hypertension—Degarelix—prostate cancer	0.000522	0.00596	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Abiraterone—prostate cancer	0.000522	0.00596	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Degarelix—prostate cancer	0.000511	0.00583	CcSEcCtD
Metyrapone—Angiopathy—Bicalutamide—prostate cancer	0.000509	0.00581	CcSEcCtD
Metyrapone—Nervous system disorder—Estradiol valerate/Dienogest—prostate cancer	0.000509	0.00581	CcSEcCtD
Metyrapone—Pain—Estrone—prostate cancer	0.000508	0.0058	CcSEcCtD
Metyrapone—Alopecia—Bicalutamide—prostate cancer	0.000496	0.00566	CcSEcCtD
Metyrapone—Hypertension—Cabazitaxel—prostate cancer	0.000491	0.00561	CcSEcCtD
Metyrapone—Nervous system disorder—Degarelix—prostate cancer	0.000484	0.00552	CcSEcCtD
Metyrapone—ABCC3—testis—prostate cancer	0.000483	0.0389	CbGeAlD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Cabazitaxel—prostate cancer	0.000481	0.0055	CcSEcCtD
Metyrapone—Skin disorder—Degarelix—prostate cancer	0.000479	0.00547	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Nilutamide—prostate cancer	0.000477	0.00544	CcSEcCtD
Metyrapone—Pain—Nilutamide—prostate cancer	0.000472	0.00539	CcSEcCtD
Metyrapone—Abdominal pain—Estrone—prostate cancer	0.00047	0.00537	CcSEcCtD
Metyrapone—CYP2E1—seminal vesicle—prostate cancer	0.000468	0.0377	CbGeAlD
Metyrapone—Abdominal discomfort—Conjugated Estrogens—prostate cancer	0.000463	0.00529	CcSEcCtD
Metyrapone—Dermatitis atopic—Prednisone—prostate cancer	0.000462	0.00528	CcSEcCtD
Metyrapone—Hypotension—Degarelix—prostate cancer	0.000461	0.00526	CcSEcCtD
Metyrapone—Nervous system disorder—Cabazitaxel—prostate cancer	0.000456	0.0052	CcSEcCtD
Metyrapone—Gastrointestinal pain—Nilutamide—prostate cancer	0.000451	0.00516	CcSEcCtD
Metyrapone—Skin disorder—Cabazitaxel—prostate cancer	0.000451	0.00515	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Estradiol valerate/Dienogest—prostate cancer	0.000448	0.00511	CcSEcCtD
Metyrapone—Pain—Estradiol valerate/Dienogest—prostate cancer	0.000444	0.00507	CcSEcCtD
Metyrapone—Abdominal pain—Nilutamide—prostate cancer	0.000436	0.00498	CcSEcCtD
Metyrapone—Hypotension—Cabazitaxel—prostate cancer	0.000434	0.00496	CcSEcCtD
Metyrapone—Angiopathy—Ethinyl Estradiol—prostate cancer	0.00043	0.00491	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Degarelix—prostate cancer	0.000426	0.00486	CcSEcCtD
Metyrapone—Gastrointestinal pain—Estradiol valerate/Dienogest—prostate cancer	0.000424	0.00484	CcSEcCtD
Metyrapone—Pain—Degarelix—prostate cancer	0.000422	0.00482	CcSEcCtD
Metyrapone—Hypertension—Bicalutamide—prostate cancer	0.000422	0.00481	CcSEcCtD
Metyrapone—Alopecia—Ethinyl Estradiol—prostate cancer	0.000419	0.00478	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Bicalutamide—prostate cancer	0.000413	0.00471	CcSEcCtD
Metyrapone—Endocrine disorder—Prednisone—prostate cancer	0.000413	0.00471	CcSEcCtD
Metyrapone—Abdominal pain—Estradiol valerate/Dienogest—prostate cancer	0.00041	0.00468	CcSEcCtD
Metyrapone—Gastrointestinal pain—Degarelix—prostate cancer	0.000403	0.00461	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Cabazitaxel—prostate cancer	0.000401	0.00458	CcSEcCtD
Metyrapone—Pain—Cabazitaxel—prostate cancer	0.000397	0.00454	CcSEcCtD
Metyrapone—Bone marrow depression—Epirubicin—prostate cancer	0.000396	0.00453	CcSEcCtD
Metyrapone—Vomiting—Estramustine—prostate cancer	0.000396	0.00452	CcSEcCtD
Metyrapone—Dizziness—Estrone—prostate cancer	0.000393	0.00449	CcSEcCtD
Metyrapone—Nervous system disorder—Bicalutamide—prostate cancer	0.000391	0.00446	CcSEcCtD
Metyrapone—Abdominal pain—Degarelix—prostate cancer	0.00039	0.00445	CcSEcCtD
Metyrapone—Headache—Estramustine—prostate cancer	0.00039	0.00445	CcSEcCtD
Metyrapone—Skin disorder—Bicalutamide—prostate cancer	0.000387	0.00442	CcSEcCtD
Metyrapone—Vomiting—Abiraterone—prostate cancer	0.000384	0.00439	CcSEcCtD
Metyrapone—Gastrointestinal pain—Cabazitaxel—prostate cancer	0.00038	0.00434	CcSEcCtD
Metyrapone—Vomiting—Estrone—prostate cancer	0.000378	0.00432	CcSEcCtD
Metyrapone—CYP2E1—renal system—prostate cancer	0.000377	0.0304	CbGeAlD
Metyrapone—Headache—Estrone—prostate cancer	0.000372	0.00425	CcSEcCtD
Metyrapone—Abdominal discomfort—Estradiol—prostate cancer	0.00037	0.00423	CcSEcCtD
Metyrapone—CYP2E1—urethra—prostate cancer	0.00037	0.0298	CbGeAlD
Metyrapone—Nausea—Estramustine—prostate cancer	0.00037	0.00422	CcSEcCtD
Metyrapone—Abdominal pain—Cabazitaxel—prostate cancer	0.000367	0.00419	CcSEcCtD
Metyrapone—Bone marrow depression—Doxorubicin—prostate cancer	0.000367	0.00419	CcSEcCtD
Metyrapone—Dizziness—Nilutamide—prostate cancer	0.000365	0.00417	CcSEcCtD
Metyrapone—Dizziness—Flutamide—prostate cancer	0.000363	0.00415	CcSEcCtD
Metyrapone—Dermatitis atopic—Epirubicin—prostate cancer	0.000362	0.00413	CcSEcCtD
Metyrapone—Angiopathy—Goserelin—prostate cancer	0.000354	0.00404	CcSEcCtD
Metyrapone—Nausea—Estrone—prostate cancer	0.000353	0.00403	CcSEcCtD
Metyrapone—Vomiting—Nilutamide—prostate cancer	0.000351	0.00401	CcSEcCtD
Metyrapone—Angiopathy—Conjugated Estrogens—prostate cancer	0.000351	0.004	CcSEcCtD
Metyrapone—ABCC3—lymph node—prostate cancer	0.00035	0.0282	CbGeAlD
Metyrapone—Vomiting—Flutamide—prostate cancer	0.000349	0.00399	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—prostate cancer	0.000349	0.00399	CcSEcCtD
Metyrapone—Headache—Nilutamide—prostate cancer	0.000346	0.00395	CcSEcCtD
Metyrapone—Alopecia—Goserelin—prostate cancer	0.000345	0.00394	CcSEcCtD
Metyrapone—Headache—Flutamide—prostate cancer	0.000344	0.00393	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Bicalutamide—prostate cancer	0.000344	0.00393	CcSEcCtD
Metyrapone—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.000343	0.00392	CcSEcCtD
Metyrapone—Pancytopenia—Mitoxantrone—prostate cancer	0.000342	0.00391	CcSEcCtD
Metyrapone—Alopecia—Conjugated Estrogens—prostate cancer	0.000342	0.0039	CcSEcCtD
Metyrapone—Pain—Bicalutamide—prostate cancer	0.000341	0.00389	CcSEcCtD
Metyrapone—Dermatitis atopic—Doxorubicin—prostate cancer	0.000335	0.00382	CcSEcCtD
Metyrapone—Nervous system disorder—Ethinyl Estradiol—prostate cancer	0.00033	0.00377	CcSEcCtD
Metyrapone—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.00033	0.00377	CcSEcCtD
Metyrapone—Nausea—Nilutamide—prostate cancer	0.000328	0.00374	CcSEcCtD
Metyrapone—Skin disorder—Ethinyl Estradiol—prostate cancer	0.000327	0.00374	CcSEcCtD
Metyrapone—Nausea—Flutamide—prostate cancer	0.000326	0.00373	CcSEcCtD
Metyrapone—Dizziness—Degarelix—prostate cancer	0.000326	0.00372	CcSEcCtD
Metyrapone—Gastrointestinal pain—Bicalutamide—prostate cancer	0.000326	0.00372	CcSEcCtD
Metyrapone—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000325	0.00371	CcSEcCtD
Metyrapone—Abdominal pain—Bicalutamide—prostate cancer	0.000315	0.0036	CcSEcCtD
Metyrapone—Vomiting—Degarelix—prostate cancer	0.000314	0.00358	CcSEcCtD
Metyrapone—Headache—Degarelix—prostate cancer	0.000309	0.00353	CcSEcCtD
Metyrapone—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000308	0.00352	CcSEcCtD
Metyrapone—Dizziness—Cabazitaxel—prostate cancer	0.000307	0.00351	CcSEcCtD
Metyrapone—CYP3A4—renal system—prostate cancer	0.000303	0.0244	CbGeAlD
Metyrapone—Vomiting—Cabazitaxel—prostate cancer	0.000295	0.00337	CcSEcCtD
Metyrapone—Hypertension—Goserelin—prostate cancer	0.000293	0.00335	CcSEcCtD
Metyrapone—Nausea—Degarelix—prostate cancer	0.000293	0.00335	CcSEcCtD
Metyrapone—Headache—Cabazitaxel—prostate cancer	0.000291	0.00332	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.000291	0.00332	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	0.000287	0.00328	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	0.000284	0.00325	CcSEcCtD
Metyrapone—Pancytopenia—Etoposide—prostate cancer	0.000284	0.00325	CcSEcCtD
Metyrapone—Angiopathy—Estradiol—prostate cancer	0.000281	0.00321	CcSEcCtD
Metyrapone—Nausea—Cabazitaxel—prostate cancer	0.000276	0.00315	CcSEcCtD
Metyrapone—Gastrointestinal pain—Ethinyl Estradiol—prostate cancer	0.000275	0.00315	CcSEcCtD
Metyrapone—Alopecia—Estradiol—prostate cancer	0.000273	0.00312	CcSEcCtD
Metyrapone—Nervous system disorder—Goserelin—prostate cancer	0.000272	0.0031	CcSEcCtD
Metyrapone—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.000269	0.00308	CcSEcCtD
Metyrapone—Skin disorder—Goserelin—prostate cancer	0.000269	0.00308	CcSEcCtD
Metyrapone—Skin disorder—Conjugated Estrogens—prostate cancer	0.000267	0.00305	CcSEcCtD
Metyrapone—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.000266	0.00304	CcSEcCtD
Metyrapone—Dizziness—Bicalutamide—prostate cancer	0.000263	0.00301	CcSEcCtD
Metyrapone—Hypotension—Goserelin—prostate cancer	0.000259	0.00296	CcSEcCtD
Metyrapone—Hypotension—Conjugated Estrogens—prostate cancer	0.000257	0.00293	CcSEcCtD
Metyrapone—Alopecia—Mitoxantrone—prostate cancer	0.000255	0.00291	CcSEcCtD
Metyrapone—Vomiting—Bicalutamide—prostate cancer	0.000253	0.00289	CcSEcCtD
Metyrapone—Headache—Bicalutamide—prostate cancer	0.00025	0.00285	CcSEcCtD
Metyrapone—CYP2E1—testis—prostate cancer	0.000244	0.0196	CbGeAlD
Metyrapone—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000237	0.00271	CcSEcCtD
Metyrapone—Pain—Goserelin—prostate cancer	0.000237	0.00271	CcSEcCtD
Metyrapone—Nausea—Bicalutamide—prostate cancer	0.000237	0.0027	CcSEcCtD
Metyrapone—Pancytopenia—Docetaxel—prostate cancer	0.000236	0.0027	CcSEcCtD
Metyrapone—Pain—Conjugated Estrogens—prostate cancer	0.000235	0.00268	CcSEcCtD
Metyrapone—Hypertension—Estradiol—prostate cancer	0.000232	0.00265	CcSEcCtD
Metyrapone—Abdominal discomfort—Capecitabine—prostate cancer	0.000231	0.00264	CcSEcCtD
Metyrapone—Pancytopenia—Capecitabine—prostate cancer	0.000229	0.00261	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000228	0.0026	CcSEcCtD
Metyrapone—Gastrointestinal pain—Goserelin—prostate cancer	0.000227	0.00259	CcSEcCtD
Metyrapone—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000225	0.00256	CcSEcCtD
Metyrapone—Dizziness—Ethinyl Estradiol—prostate cancer	0.000223	0.00254	CcSEcCtD
Metyrapone—Abdominal pain—Goserelin—prostate cancer	0.000219	0.0025	CcSEcCtD
Metyrapone—Angiopathy—Etoposide—prostate cancer	0.000217	0.00248	CcSEcCtD
Metyrapone—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000217	0.00248	CcSEcCtD
Metyrapone—Hypertension—Mitoxantrone—prostate cancer	0.000217	0.00247	CcSEcCtD
Metyrapone—Nervous system disorder—Estradiol—prostate cancer	0.000215	0.00246	CcSEcCtD
Metyrapone—Vomiting—Ethinyl Estradiol—prostate cancer	0.000214	0.00245	CcSEcCtD
Metyrapone—Skin disorder—Estradiol—prostate cancer	0.000213	0.00244	CcSEcCtD
Metyrapone—Alopecia—Etoposide—prostate cancer	0.000212	0.00242	CcSEcCtD
Metyrapone—Headache—Ethinyl Estradiol—prostate cancer	0.000211	0.00241	CcSEcCtD
Metyrapone—Nausea—Ethinyl Estradiol—prostate cancer	0.0002	0.00228	CcSEcCtD
Metyrapone—Skin disorder—Mitoxantrone—prostate cancer	0.000199	0.00227	CcSEcCtD
Metyrapone—Hypotension—Mitoxantrone—prostate cancer	0.000191	0.00219	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Estradiol—prostate cancer	0.00019	0.00217	CcSEcCtD
Metyrapone—Pain—Estradiol—prostate cancer	0.000188	0.00215	CcSEcCtD
Metyrapone—Dizziness—Goserelin—prostate cancer	0.000183	0.00209	CcSEcCtD
Metyrapone—Dizziness—Conjugated Estrogens—prostate cancer	0.000182	0.00207	CcSEcCtD
Metyrapone—Angiopathy—Docetaxel—prostate cancer	0.000181	0.00206	CcSEcCtD
Metyrapone—Hypertension—Etoposide—prostate cancer	0.00018	0.00206	CcSEcCtD
Metyrapone—Gastrointestinal pain—Estradiol—prostate cancer	0.00018	0.00205	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000176	0.00202	CcSEcCtD
Metyrapone—Vomiting—Goserelin—prostate cancer	0.000176	0.00201	CcSEcCtD
Metyrapone—Alopecia—Docetaxel—prostate cancer	0.000176	0.00201	CcSEcCtD
Metyrapone—Pain—Mitoxantrone—prostate cancer	0.000175	0.002	CcSEcCtD
Metyrapone—Angiopathy—Capecitabine—prostate cancer	0.000175	0.002	CcSEcCtD
Metyrapone—Vomiting—Conjugated Estrogens—prostate cancer	0.000175	0.00199	CcSEcCtD
Metyrapone—Abdominal pain—Estradiol—prostate cancer	0.000174	0.00198	CcSEcCtD
Metyrapone—Headache—Goserelin—prostate cancer	0.000174	0.00198	CcSEcCtD
Metyrapone—Headache—Conjugated Estrogens—prostate cancer	0.000172	0.00196	CcSEcCtD
Metyrapone—Alopecia—Capecitabine—prostate cancer	0.00017	0.00195	CcSEcCtD
Metyrapone—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000167	0.00191	CcSEcCtD
Metyrapone—Skin disorder—Etoposide—prostate cancer	0.000165	0.00189	CcSEcCtD
Metyrapone—Nausea—Goserelin—prostate cancer	0.000165	0.00188	CcSEcCtD
Metyrapone—Nausea—Conjugated Estrogens—prostate cancer	0.000163	0.00186	CcSEcCtD
Metyrapone—Abdominal pain—Mitoxantrone—prostate cancer	0.000162	0.00185	CcSEcCtD
Metyrapone—Pancytopenia—Epirubicin—prostate cancer	0.000159	0.00182	CcSEcCtD
Metyrapone—Hypotension—Etoposide—prostate cancer	0.000159	0.00182	CcSEcCtD
Metyrapone—Angiopathy—Prednisone—prostate cancer	0.000156	0.00178	CcSEcCtD
Metyrapone—Alopecia—Prednisone—prostate cancer	0.000152	0.00173	CcSEcCtD
Metyrapone—Hypertension—Docetaxel—prostate cancer	0.00015	0.00171	CcSEcCtD
Metyrapone—Pancytopenia—Doxorubicin—prostate cancer	0.000148	0.00168	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Etoposide—prostate cancer	0.000147	0.00168	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000147	0.00167	CcSEcCtD
Metyrapone—Pain—Etoposide—prostate cancer	0.000146	0.00166	CcSEcCtD
Metyrapone—Dizziness—Estradiol—prostate cancer	0.000145	0.00166	CcSEcCtD
Metyrapone—Hypertension—Capecitabine—prostate cancer	0.000145	0.00166	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000142	0.00162	CcSEcCtD
Metyrapone—Vomiting—Estradiol—prostate cancer	0.00014	0.0016	CcSEcCtD
Metyrapone—Gastrointestinal pain—Etoposide—prostate cancer	0.000139	0.00159	CcSEcCtD
Metyrapone—Nervous system disorder—Docetaxel—prostate cancer	0.000139	0.00159	CcSEcCtD
Metyrapone—Headache—Estradiol—prostate cancer	0.000138	0.00157	CcSEcCtD
Metyrapone—Skin disorder—Docetaxel—prostate cancer	0.000137	0.00157	CcSEcCtD
Metyrapone—Abdominal pain—Etoposide—prostate cancer	0.000135	0.00154	CcSEcCtD
Metyrapone—Nervous system disorder—Capecitabine—prostate cancer	0.000134	0.00153	CcSEcCtD
Metyrapone—Skin disorder—Capecitabine—prostate cancer	0.000133	0.00152	CcSEcCtD
Metyrapone—Hypotension—Docetaxel—prostate cancer	0.000132	0.00151	CcSEcCtD
Metyrapone—Nausea—Estradiol—prostate cancer	0.000131	0.00149	CcSEcCtD
Metyrapone—Vomiting—Mitoxantrone—prostate cancer	0.00013	0.00149	CcSEcCtD
Metyrapone—Hypertension—Prednisone—prostate cancer	0.000129	0.00147	CcSEcCtD
Metyrapone—Headache—Mitoxantrone—prostate cancer	0.000128	0.00146	CcSEcCtD
Metyrapone—Hypotension—Capecitabine—prostate cancer	0.000128	0.00146	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000126	0.00144	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000122	0.0014	CcSEcCtD
Metyrapone—Angiopathy—Epirubicin—prostate cancer	0.000122	0.00139	CcSEcCtD
Metyrapone—Nausea—Mitoxantrone—prostate cancer	0.000122	0.00139	CcSEcCtD
Metyrapone—Pain—Docetaxel—prostate cancer	0.000121	0.00138	CcSEcCtD
Metyrapone—Nervous system disorder—Prednisone—prostate cancer	0.00012	0.00137	CcSEcCtD
Metyrapone—Alopecia—Epirubicin—prostate cancer	0.000119	0.00136	CcSEcCtD
Metyrapone—Skin disorder—Prednisone—prostate cancer	0.000119	0.00135	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000118	0.00135	CcSEcCtD
Metyrapone—Pain—Capecitabine—prostate cancer	0.000117	0.00134	CcSEcCtD
Metyrapone—Gastrointestinal pain—Docetaxel—prostate cancer	0.000116	0.00132	CcSEcCtD
Metyrapone—Angiopathy—Doxorubicin—prostate cancer	0.000113	0.00129	CcSEcCtD
Metyrapone—Dizziness—Etoposide—prostate cancer	0.000113	0.00129	CcSEcCtD
Metyrapone—Gastrointestinal pain—Capecitabine—prostate cancer	0.000112	0.00128	CcSEcCtD
Metyrapone—Abdominal pain—Docetaxel—prostate cancer	0.000112	0.00128	CcSEcCtD
Metyrapone—Alopecia—Doxorubicin—prostate cancer	0.00011	0.00125	CcSEcCtD
Metyrapone—Abdominal pain—Capecitabine—prostate cancer	0.000108	0.00124	CcSEcCtD
Metyrapone—Vomiting—Etoposide—prostate cancer	0.000108	0.00124	CcSEcCtD
Metyrapone—Headache—Etoposide—prostate cancer	0.000107	0.00122	CcSEcCtD
Metyrapone—Nausea—Etoposide—prostate cancer	0.000101	0.00116	CcSEcCtD
Metyrapone—Hypertension—Epirubicin—prostate cancer	0.000101	0.00115	CcSEcCtD
Metyrapone—Gastrointestinal pain—Prednisone—prostate cancer	9.98e-05	0.00114	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	9.89e-05	0.00113	CcSEcCtD
Metyrapone—Abdominal pain—Prednisone—prostate cancer	9.65e-05	0.0011	CcSEcCtD
Metyrapone—Nervous system disorder—Epirubicin—prostate cancer	9.36e-05	0.00107	CcSEcCtD
Metyrapone—Dizziness—Docetaxel—prostate cancer	9.36e-05	0.00107	CcSEcCtD
Metyrapone—Hypertension—Doxorubicin—prostate cancer	9.34e-05	0.00107	CcSEcCtD
Metyrapone—Skin disorder—Epirubicin—prostate cancer	9.27e-05	0.00106	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	9.15e-05	0.00105	CcSEcCtD
Metyrapone—Dizziness—Capecitabine—prostate cancer	9.06e-05	0.00103	CcSEcCtD
Metyrapone—Vomiting—Docetaxel—prostate cancer	9e-05	0.00103	CcSEcCtD
Metyrapone—Hypotension—Epirubicin—prostate cancer	8.92e-05	0.00102	CcSEcCtD
Metyrapone—Headache—Docetaxel—prostate cancer	8.87e-05	0.00101	CcSEcCtD
Metyrapone—Vomiting—Capecitabine—prostate cancer	8.71e-05	0.000995	CcSEcCtD
Metyrapone—Nervous system disorder—Doxorubicin—prostate cancer	8.66e-05	0.000989	CcSEcCtD
Metyrapone—Headache—Capecitabine—prostate cancer	8.58e-05	0.00098	CcSEcCtD
Metyrapone—Skin disorder—Doxorubicin—prostate cancer	8.58e-05	0.00098	CcSEcCtD
Metyrapone—Nausea—Docetaxel—prostate cancer	8.41e-05	0.00096	CcSEcCtD
Metyrapone—Hypotension—Doxorubicin—prostate cancer	8.25e-05	0.000943	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Epirubicin—prostate cancer	8.24e-05	0.000941	CcSEcCtD
Metyrapone—Pain—Epirubicin—prostate cancer	8.16e-05	0.000932	CcSEcCtD
Metyrapone—Nausea—Capecitabine—prostate cancer	8.14e-05	0.00093	CcSEcCtD
Metyrapone—Dizziness—Prednisone—prostate cancer	8.07e-05	0.000922	CcSEcCtD
Metyrapone—Gastrointestinal pain—Epirubicin—prostate cancer	7.81e-05	0.000892	CcSEcCtD
Metyrapone—Vomiting—Prednisone—prostate cancer	7.76e-05	0.000886	CcSEcCtD
Metyrapone—Headache—Prednisone—prostate cancer	7.65e-05	0.000873	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Doxorubicin—prostate cancer	7.63e-05	0.000871	CcSEcCtD
Metyrapone—Pain—Doxorubicin—prostate cancer	7.55e-05	0.000863	CcSEcCtD
Metyrapone—Abdominal pain—Epirubicin—prostate cancer	7.55e-05	0.000862	CcSEcCtD
Metyrapone—Nausea—Prednisone—prostate cancer	7.25e-05	0.000828	CcSEcCtD
Metyrapone—Gastrointestinal pain—Doxorubicin—prostate cancer	7.22e-05	0.000825	CcSEcCtD
Metyrapone—Abdominal pain—Doxorubicin—prostate cancer	6.98e-05	0.000798	CcSEcCtD
Metyrapone—Dizziness—Epirubicin—prostate cancer	6.31e-05	0.000721	CcSEcCtD
Metyrapone—Vomiting—Epirubicin—prostate cancer	6.07e-05	0.000693	CcSEcCtD
Metyrapone—Headache—Epirubicin—prostate cancer	5.98e-05	0.000683	CcSEcCtD
Metyrapone—Dizziness—Doxorubicin—prostate cancer	5.84e-05	0.000667	CcSEcCtD
Metyrapone—Nausea—Epirubicin—prostate cancer	5.67e-05	0.000648	CcSEcCtD
Metyrapone—Vomiting—Doxorubicin—prostate cancer	5.62e-05	0.000641	CcSEcCtD
Metyrapone—Headache—Doxorubicin—prostate cancer	5.53e-05	0.000632	CcSEcCtD
Metyrapone—Nausea—Doxorubicin—prostate cancer	5.25e-05	0.000599	CcSEcCtD
Metyrapone—CYP2E1—Metabolism—HSD3B1—prostate cancer	7.17e-06	5.57e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SLC22A3—prostate cancer	7.17e-06	5.57e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—MED12—prostate cancer	7.09e-06	5.51e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—CREBBP—prostate cancer	7.07e-06	5.5e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	7.04e-06	5.47e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GNG5—prostate cancer	7.03e-06	5.47e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—COMT—prostate cancer	6.97e-06	5.42e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GSTP1—prostate cancer	6.94e-06	5.39e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.89e-06	5.36e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—TBXAS1—prostate cancer	6.87e-06	5.34e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTA4—prostate cancer	6.87e-06	5.34e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ITPR1—prostate cancer	6.82e-06	5.31e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NCOA3—prostate cancer	6.77e-06	5.27e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—EP300—prostate cancer	6.71e-06	5.22e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PIK3CD—prostate cancer	6.7e-06	5.21e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTA2—prostate cancer	6.7e-06	5.21e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SULT1A1—prostate cancer	6.61e-06	5.14e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ABCG5—prostate cancer	6.61e-06	5.14e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PIK3CG—prostate cancer	6.57e-06	5.11e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CBR1—prostate cancer	6.53e-06	5.08e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GRHL1—prostate cancer	6.53e-06	5.08e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—TST—prostate cancer	6.53e-06	5.08e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ADI1—prostate cancer	6.53e-06	5.08e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CSAD—prostate cancer	6.53e-06	5.08e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PSAT1—prostate cancer	6.53e-06	5.08e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—HPGDS—prostate cancer	6.46e-06	5.02e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTA1—prostate cancer	6.46e-06	5.02e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—TYMS—prostate cancer	6.45e-06	5.01e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP2C19—prostate cancer	6.42e-06	4.99e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—HSD3B2—prostate cancer	6.39e-06	4.97e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTO1—prostate cancer	6.39e-06	4.97e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NAT2—prostate cancer	6.39e-06	4.97e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GSTM1—prostate cancer	6.37e-06	4.96e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—NOS3—prostate cancer	6.33e-06	4.92e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ACHE—prostate cancer	6.27e-06	4.87e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTT1—prostate cancer	6.27e-06	4.87e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—LPL—prostate cancer	6.26e-06	4.86e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—INS—prostate cancer	6.22e-06	4.84e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PLCB2—prostate cancer	6.12e-06	4.76e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—LRP2—prostate cancer	6.12e-06	4.76e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP2C18—prostate cancer	6.12e-06	4.76e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CREBBP—prostate cancer	6.09e-06	4.74e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—UGT2B17—prostate cancer	6.07e-06	4.72e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CKMT2—prostate cancer	6.07e-06	4.72e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GRHPR—prostate cancer	6.07e-06	4.72e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—UGT2B15—prostate cancer	6.07e-06	4.72e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CYP1A1—prostate cancer	6.04e-06	4.7e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—AKR1C3—prostate cancer	6.03e-06	4.69e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—P4HB—prostate cancer	6.01e-06	4.67e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PRKACB—prostate cancer	6e-06	4.66e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ERCC2—prostate cancer	5.99e-06	4.66e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP17A1—prostate cancer	5.93e-06	4.61e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PIK3CB—prostate cancer	5.84e-06	4.54e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SLC22A1—prostate cancer	5.84e-06	4.54e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PTGS2—prostate cancer	5.79e-06	4.5e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PIK3CD—prostate cancer	5.78e-06	4.49e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PGAM2—prostate cancer	5.71e-06	4.44e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—MBTPS1—prostate cancer	5.71e-06	4.44e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—RFK—prostate cancer	5.71e-06	4.44e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SULT2B1—prostate cancer	5.71e-06	4.44e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NAGLU—prostate cancer	5.71e-06	4.44e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTM3—prostate cancer	5.71e-06	4.44e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—AOX1—prostate cancer	5.71e-06	4.44e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SULT2A1—prostate cancer	5.69e-06	4.43e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NCOA2—prostate cancer	5.65e-06	4.4e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—MTHFR—prostate cancer	5.63e-06	4.38e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—MED12—prostate cancer	5.6e-06	4.36e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GNG5—prostate cancer	5.56e-06	4.32e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PPARA—prostate cancer	5.53e-06	4.3e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—NOS3—prostate cancer	5.46e-06	4.24e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—AMACR—prostate cancer	5.41e-06	4.21e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP3A43—prostate cancer	5.41e-06	4.21e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NAT1—prostate cancer	5.41e-06	4.21e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—DEGS1—prostate cancer	5.41e-06	4.21e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SRD5A2—prostate cancer	5.41e-06	4.21e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—SLC5A5—prostate cancer	5.39e-06	4.19e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NCOA3—prostate cancer	5.35e-06	4.16e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP2E1—prostate cancer	5.27e-06	4.1e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NQO1—prostate cancer	5.21e-06	4.05e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CAV1—prostate cancer	5.2e-06	4.04e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HSD17B1—prostate cancer	5.16e-06	4.01e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—TH—prostate cancer	5.13e-06	3.99e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—HPGDS—prostate cancer	5.11e-06	3.97e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP3A4—prostate cancer	5.08e-06	3.95e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP2C19—prostate cancer	5.07e-06	3.95e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PTEN—prostate cancer	5.05e-06	3.93e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PIK3CB—prostate cancer	5.04e-06	3.92e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP1B1—prostate cancer	4.99e-06	3.88e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PTGS2—prostate cancer	4.99e-06	3.88e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.96e-06	3.86e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTT1—prostate cancer	4.95e-06	3.85e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ACHE—prostate cancer	4.95e-06	3.85e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP2A6—prostate cancer	4.9e-06	3.81e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GGT1—prostate cancer	4.84e-06	3.76e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—EP300—prostate cancer	4.82e-06	3.74e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NCOA1—prostate cancer	4.76e-06	3.7e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—AKR1C3—prostate cancer	4.76e-06	3.7e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PRKACB—prostate cancer	4.74e-06	3.68e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PIK3CG—prostate cancer	4.73e-06	3.68e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP19A1—prostate cancer	4.7e-06	3.65e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP17A1—prostate cancer	4.69e-06	3.65e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HPGD—prostate cancer	4.6e-06	3.58e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—B4GALT4—prostate cancer	4.6e-06	3.58e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—RXRA—prostate cancer	4.53e-06	3.52e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—INS—prostate cancer	4.48e-06	3.48e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NCOA2—prostate cancer	4.47e-06	3.47e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CREBBP—prostate cancer	4.39e-06	3.41e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—COMT—prostate cancer	4.37e-06	3.39e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PTEN—prostate cancer	4.35e-06	3.38e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTP1—prostate cancer	4.34e-06	3.38e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—TNFRSF21—prostate cancer	4.32e-06	3.36e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ITPR1—prostate cancer	4.28e-06	3.32e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SLC5A5—prostate cancer	4.26e-06	3.31e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP7B1—prostate cancer	4.21e-06	3.27e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—MTAP—prostate cancer	4.21e-06	3.27e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PIK3CD—prostate cancer	4.16e-06	3.23e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—EP300—prostate cancer	4.15e-06	3.23e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NQO1—prostate cancer	4.12e-06	3.2e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SRD5A1—prostate cancer	4.1e-06	3.19e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SULT1E1—prostate cancer	4.1e-06	3.19e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—TH—prostate cancer	4.06e-06	3.15e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—TYMS—prostate cancer	4.04e-06	3.14e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP3A4—prostate cancer	4.01e-06	3.12e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTM1—prostate cancer	3.99e-06	3.1e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP1B1—prostate cancer	3.95e-06	3.07e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—NOS3—prostate cancer	3.93e-06	3.05e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—LPL—prostate cancer	3.92e-06	3.05e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ACSL4—prostate cancer	3.91e-06	3.04e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HSD17B3—prostate cancer	3.91e-06	3.04e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GGT1—prostate cancer	3.82e-06	2.97e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP1A1—prostate cancer	3.78e-06	2.94e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NCOA1—prostate cancer	3.77e-06	2.93e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ERCC2—prostate cancer	3.75e-06	2.92e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ARG2—prostate cancer	3.75e-06	2.92e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PHGDH—prostate cancer	3.75e-06	2.92e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—UMPS—prostate cancer	3.75e-06	2.92e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP19A1—prostate cancer	3.71e-06	2.89e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—LDHB—prostate cancer	3.68e-06	2.86e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PIK3CB—prostate cancer	3.63e-06	2.82e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP3A5—prostate cancer	3.61e-06	2.81e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PTGS2—prostate cancer	3.59e-06	2.79e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—RXRA—prostate cancer	3.58e-06	2.78e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PIK3CA—prostate cancer	3.56e-06	2.77e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—MTHFR—prostate cancer	3.53e-06	2.74e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PDHA1—prostate cancer	3.49e-06	2.71e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—UCP3—prostate cancer	3.49e-06	2.71e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—TCN2—prostate cancer	3.49e-06	2.71e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTA3—prostate cancer	3.49e-06	2.71e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PPARA—prostate cancer	3.46e-06	2.69e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—COMT—prostate cancer	3.45e-06	2.68e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTP1—prostate cancer	3.43e-06	2.67e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ITPR1—prostate cancer	3.38e-06	2.63e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLC22A3—prostate cancer	3.33e-06	2.59e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HSD3B1—prostate cancer	3.33e-06	2.59e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CAV1—prostate cancer	3.25e-06	2.53e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—TYMS—prostate cancer	3.19e-06	2.48e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—TBXAS1—prostate cancer	3.19e-06	2.48e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTA4—prostate cancer	3.19e-06	2.48e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTM1—prostate cancer	3.16e-06	2.45e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PTEN—prostate cancer	3.13e-06	2.44e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTA2—prostate cancer	3.11e-06	2.42e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—LPL—prostate cancer	3.1e-06	2.41e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PIK3CA—prostate cancer	3.07e-06	2.39e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ABCG5—prostate cancer	3.07e-06	2.39e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SULT1A1—prostate cancer	3.07e-06	2.39e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTA1—prostate cancer	3e-06	2.33e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP1A1—prostate cancer	2.99e-06	2.33e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—EP300—prostate cancer	2.99e-06	2.32e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ERCC2—prostate cancer	2.97e-06	2.31e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PIK3CG—prostate cancer	2.96e-06	2.31e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HSD3B2—prostate cancer	2.96e-06	2.3e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTO1—prostate cancer	2.96e-06	2.3e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NAT2—prostate cancer	2.96e-06	2.3e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—AKT1—prostate cancer	2.91e-06	2.26e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PLCB2—prostate cancer	2.84e-06	2.21e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—LRP2—prostate cancer	2.84e-06	2.21e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP2C18—prostate cancer	2.84e-06	2.21e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—INS—prostate cancer	2.81e-06	2.18e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—MTHFR—prostate cancer	2.79e-06	2.17e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—P4HB—prostate cancer	2.79e-06	2.17e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CREBBP—prostate cancer	2.75e-06	2.14e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PPARA—prostate cancer	2.74e-06	2.13e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.71e-06	2.11e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.64e-06	2.05e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PIK3CD—prostate cancer	2.61e-06	2.03e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—MED12—prostate cancer	2.6e-06	2.02e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GNG5—prostate cancer	2.58e-06	2e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CAV1—prostate cancer	2.57e-06	2e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—AKT1—prostate cancer	2.51e-06	1.95e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NCOA3—prostate cancer	2.48e-06	1.93e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NOS3—prostate cancer	2.46e-06	1.91e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HPGDS—prostate cancer	2.37e-06	1.84e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.35e-06	1.83e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PIK3CG—prostate cancer	2.34e-06	1.82e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTT1—prostate cancer	2.3e-06	1.79e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ACHE—prostate cancer	2.3e-06	1.79e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.27e-06	1.77e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PIK3CB—prostate cancer	2.27e-06	1.77e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PTGS2—prostate cancer	2.25e-06	1.75e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—INS—prostate cancer	2.22e-06	1.72e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PIK3CA—prostate cancer	2.21e-06	1.72e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.21e-06	1.72e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PRKACB—prostate cancer	2.2e-06	1.71e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.18e-06	1.69e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CREBBP—prostate cancer	2.17e-06	1.69e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NCOA2—prostate cancer	2.07e-06	1.61e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PIK3CD—prostate cancer	2.06e-06	1.6e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.98e-06	1.54e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PTEN—prostate cancer	1.96e-06	1.53e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NOS3—prostate cancer	1.94e-06	1.51e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.93e-06	1.5e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NQO1—prostate cancer	1.91e-06	1.49e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—TH—prostate cancer	1.88e-06	1.46e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—EP300—prostate cancer	1.87e-06	1.46e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.83e-06	1.42e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—AKT1—prostate cancer	1.81e-06	1.4e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PIK3CB—prostate cancer	1.8e-06	1.4e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PTGS2—prostate cancer	1.78e-06	1.38e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GGT1—prostate cancer	1.77e-06	1.38e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NCOA1—prostate cancer	1.75e-06	1.36e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.72e-06	1.34e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—RXRA—prostate cancer	1.66e-06	1.29e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—COMT—prostate cancer	1.6e-06	1.24e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTP1—prostate cancer	1.59e-06	1.24e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ITPR1—prostate cancer	1.57e-06	1.22e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PTEN—prostate cancer	1.55e-06	1.21e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—TYMS—prostate cancer	1.48e-06	1.15e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—EP300—prostate cancer	1.48e-06	1.15e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTM1—prostate cancer	1.46e-06	1.14e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—LPL—prostate cancer	1.44e-06	1.12e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.39e-06	1.08e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PIK3CA—prostate cancer	1.38e-06	1.08e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ERCC2—prostate cancer	1.38e-06	1.07e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—MTHFR—prostate cancer	1.29e-06	1.01e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PPARA—prostate cancer	1.27e-06	9.87e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CAV1—prostate cancer	1.19e-06	9.28e-06	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—AKT1—prostate cancer	1.13e-06	8.8e-06	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PIK3CA—prostate cancer	1.09e-06	8.51e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.09e-06	8.45e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—INS—prostate cancer	1.03e-06	8e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CREBBP—prostate cancer	1.01e-06	7.84e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PIK3CD—prostate cancer	9.56e-07	7.43e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NOS3—prostate cancer	9.02e-07	7.02e-06	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—AKT1—prostate cancer	8.94e-07	6.95e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PIK3CB—prostate cancer	8.33e-07	6.48e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PTGS2—prostate cancer	8.25e-07	6.42e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PTEN—prostate cancer	7.2e-07	5.6e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—EP300—prostate cancer	6.86e-07	5.34e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PIK3CA—prostate cancer	5.08e-07	3.95e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—AKT1—prostate cancer	4.15e-07	3.22e-06	CbGpPWpGaD
